Cancer Diagnostics Market Size, Revenue, Trends Insight, Report 2024-2032


(MENAFN- IMARC Group) IMARC Group, a leading market research company, has recently releases report titled “Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032” The global cancer diagnostics market size reached US$ 197.7 Billion in 2023 . Looking forward, IMARC Group expects the market to reach US$ 314.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Request For Sample Copy of Report:
https://www.imarcgroup.com/cancer-diagnostics-market/requestsample

Factors Affecting the Growth of the Cancer Diagnostics Industry:

  • Increasing Incidence of Cancer:

The increasing incidence of cancer, primarily due to factors, such as aging populations, lifestyle changes, and environmental factors, represents one of the crucial factors impelling the growth of the market. Besides this, as the number of cancer cases rises, there is a corresponding increase in the demand for accurate and efficient diagnostic tools. This trend is compelling healthcare providers and researchers to explore innovative technologies that can enhance the early detection of cancer, thus improving treatment outcomes. Moreover, the growing consumption of alcohol among the masses is contributing to the market growth.

  • Advancements in Genomics and Proteomics:

Advances in genomic and proteomic technologies are enabling the identification of specific molecular profiles associated with different cancers. This is also paving the way for targeted therapies that are tailored to individual patients based on their unique genetic makeup. The shift towards personalized medicine is not only improving treatment outcomes but also influencing diagnostic approaches. Companion diagnostics, which help identify patients who are most likely to benefit from a particular treatment, are becoming integral to cancer diagnostics. Governments, non-profit organizations, and healthcare providers are actively promoting cancer screening programs to educate the public about the benefits of early diagnosis.

  • Technological Advancements:

The integration of cutting-edge technologies, such as next-generation sequencing, liquid biopsy, and advanced imaging techniques, is revolutionizing cancer diagnosis. These technologies offer higher sensitivity and specificity, enabling healthcare professionals to detect cancer at earlier stages and with greater precision. Molecular diagnostics, in particular, is gaining prominence, allowing for the identification of genetic mutations and biomarkers associated with specific cancer types. This trend is also facilitating early diagnosis and supporting the development of targeted therapies, ushering in a new era of personalized medicine.

Leading Companies Operating in the Global Cancer Diagnostics Industry:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • GE HealthCare (General Electric Company)
  • Hologic Inc.
  • Illumina Inc.
  • Koninklijke Philips N.V.
  • Pfizer Inc.
  • Qiagen N.V
  • Quest Diagnostics
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific Inc.

Cancer Diagnostics Market Report Segmentation:

By Product:

  • Consumables
    • Antibodies
    • Kits and Reagents
    • Probes
    • Others
  • Instruments
    • Pathology-based Instruments
    • Imaging Instruments
    • Biopsy Instruments

Based on the product, the market has been segmented into consumables and instruments.

By Technology:

  • IVD Testing
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Next-generation Sequencing (NGS)
    • Microarrays
    • Flow Cytometry
    • Immunoassays
    • Others
  • Imaging
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Mammography
    • Ultrasound
  • Biopsy Technique

Imaging accounted for the largest market share due to its effectiveness in detecting the presence of cancerous cells within the body.

By Application:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Breast cancer represented the largest segment due to the rising exposure to environmental factors, such as endocrine-disrupting chemicals, which may contribute to the development of breast cancer.

By End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others

Hospitals and clinics represent the maximum market share due to the increasing number of patients dealing with cancer.

Regional Insights:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

North America's dominance in the cancer diagnostics market is attributed to substantial investment in cancer research and development (R&D) activities, leading to advanced technological developments in this field.

Global Cancer Diagnostics Market Trends:

The emphasis on preventive healthcare and routine screenings is leading to a higher rate of cancer detection at early stages, positively impacting treatment success rates. This trend is particularly significant in developing regions, where awareness and access to healthcare services are improving.

Governing agencies of various countries and healthcare organizations are recognizing the economic benefits of investing in advanced diagnostics to detect cancer in its early and more treatable stages. This economic perspective is driving policies and initiatives aimed at enhancing cancer diagnostic infrastructure and accessibility.

Other Key Points Covered in the Report:

  • COVID-19 Impact
  • Porters Five Forces Analysis
  • Value Chain Analysis
  • Strategic Recommendations

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

MENAFN01032024004122016232ID1107921570


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.